{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T23:12:29Z","timestamp":1781651549558,"version":"3.54.5"},"reference-count":24,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"7","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2018,7]]},"abstract":"<jats:sec>\n            <jats:title>Objective:<\/jats:title>\n            <jats:p>A comparative assessment of treatment alternatives for T1N0 anal canal cancer has never been conducted. We compared the outcomes associated with the treatment alternatives\u2014chemoradiotherapy (CRT), radiotherapy (RT), and surgery or ablation techniques (surgery\/ablation)\u2014for T1N0 anal canal cancer.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Materials and Methods:<\/jats:title>\n            <jats:p>This retrospective cohort study was conducted using the Surveillance, Epidemiology and End Results (SEER) registries linked with Medicare longitudinal data (SEER-Medicare database). Analysis included 190 patients who were treated for T1N0 anal canal cancer using surgery\/ablation (n=44), RT (n=50), or CRT (n=96). The outcomes were reported in terms of survival and hazards ratios using Kaplan-Meier and Cox proportional hazards modeling, respectively; lifetime costs; and cost-effectiveness measured in terms of incremental cost-effectiveness ratio, that is, the ratio of the difference in costs between the 2 alternatives to the difference in effectiveness between the same 2 alternatives.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results:<\/jats:title>\n            <jats:p>There was no significant difference in the survival duration between the treatment groups as predicted by the Kaplan-Meier curves. After adjusting for patient characteristics and propensity score, the hazard ratio of death for the patients who received CRT compared with surgery\/ablation was 1.742 (95% confidence interval, 0.793-3.829) and RT was 2.170 (95% confidence interval, 0.923-5.101); however, the relationship did not reach statistical significance. Surgery\/ablation resulted in lower lifetime cost than RT or CRT. The incremental cost-effectiveness ratio associated with CRT compared with surgery\/ablation was $142,883 per life year gained.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusions:<\/jats:title>\n            <jats:p>There was no statistically significant difference in survival among the treatment alternatives for T1N0 anal canal cancer. Given that surgery\/ablation costs less than RT or CRT and might be cost-effective compared with RT and CRT, it is crucial to explore this finding further in this era of limited health care resources.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/coc.0000000000000339","type":"journal-article","created":{"date-parts":[[2016,10,18]],"date-time":"2016-10-18T07:37:53Z","timestamp":1476776273000},"page":"626-631","source":"Crossref","is-referenced-by-count":18,"title":["Clinical and Economic Evaluation of Treatment Strategies for T1N0 Anal Canal Cancer"],"prefix":"10.1097","volume":"41","author":[{"given":"Ashish A.","family":"Deshmukh","sequence":"first","affiliation":[{"name":"Department of Health Services Research, Management and Policy, University of Florida, Gainesville, FL"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hui","family":"Zhao","sequence":"additional","affiliation":[{"name":"Health Services Research"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Prajnan","family":"Das","sequence":"additional","affiliation":[{"name":"Radiation Oncology"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elizabeth Y.","family":"Chiao","sequence":"additional","affiliation":[{"name":"Department of Medicine, Section of Infectious Disease, Baylor College of Medicine"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yi-Qian Nancy","family":"You","sequence":"additional","affiliation":[{"name":"Surgical Oncology, The University of Texas MD Anderson Cancer Center"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luisa","family":"Franzini","sequence":"additional","affiliation":[{"name":"Department of Health Services Administration, University of Maryland School of Public Health, College Park, MD"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David R.","family":"Lairson","sequence":"additional","affiliation":[{"name":"The University of Texas Health Science Center of Houston School of Public Health, Houston, TX"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael D.","family":"Swartz","sequence":"additional","affiliation":[{"name":"The University of Texas Health Science Center of Houston School of Public Health, Houston, TX"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sharon H.","family":"Giordano","sequence":"additional","affiliation":[{"name":"Health Services Research"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Scott B.","family":"Cantor","sequence":"additional","affiliation":[{"name":"Health Services Research"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-20230903","doi-asserted-by":"crossref","first-page":"1569","DOI":"10.1200\/JCO.2012.45.2524","article-title":"Changing patterns of anal canal carcinoma in the United States","volume":"31","author":"Nelson","year":"2013","journal-title":"J Clin Oncol"},{"key":"R3-20230903","doi-asserted-by":"crossref","first-page":"1116","DOI":"10.1200\/JCO.2008.19.6857","article-title":"US intergroup anal carcinoma trial: tumor diameter predicts for colostomy","volume":"27","author":"Ajani","year":"2009","journal-title":"J Clin Oncol"},{"key":"R4-20230903","doi-asserted-by":"crossref","first-page":"1941","DOI":"10.1200\/JCO.2011.35.4837","article-title":"Induction chemotherapy and dose intensification of the radiation boost in locally advanced anal canal carcinoma: final analysis of the randomized UNICANCER ACCORD 03 trial","volume":"30","author":"Peiffert","year":"2012","journal-title":"J Clin Oncol"},{"key":"R5-20230903","doi-asserted-by":"crossref","first-page":"1049","DOI":"10.1016\/S0140-6736(96)03409-5","article-title":"Epidermoid anal cancer: results from the UKCCCR randomised trial of radiotherapy alone versus radiotherapy, 5-fluorouracil, and mitomycin. UKCCCR Anal Cancer Trial Working Party. UK Co-ordinating Committee on Cancer Research","volume":"348","year":"1996","journal-title":"Lancet"},{"key":"R6-20230903","doi-asserted-by":"crossref","first-page":"1914","DOI":"10.1001\/jama.299.16.1914","article-title":"Fluorouracil, mitomycin, and radiotherapy vs fluorouracil, cisplatin, and radiotherapy for carcinoma of the anal canal: a randomized controlled trial","volume":"299","author":"Ajani","year":"2008","journal-title":"JAMA"},{"key":"R7-20230903","doi-asserted-by":"crossref","first-page":"2040","DOI":"10.1200\/JCO.1997.15.5.2040","article-title":"Concomitant radiotherapy and chemotherapy is superior to radiotherapy alone in the treatment of locally advanced anal cancer: results of a phase III randomized trial of the European Organization for Research and Treatment of Cancer Radiotherapy and Gastrointestinal Cooperative Groups","volume":"15","author":"Bartelink","year":"1997","journal-title":"J Clin Oncol"},{"key":"R8-20230903","doi-asserted-by":"crossref","first-page":"2527","DOI":"10.1200\/JCO.1996.14.9.2527","article-title":"Role of mitomycin in combination with fluorouracil and radiotherapy, and of salvage chemoradiation in the definitive nonsurgical treatment of epidermoid carcinoma of the anal canal: results of a phase III randomized intergroup study","volume":"14","author":"Flam","year":"1996","journal-title":"J Clin Oncol"},{"key":"R9-20230903","doi-asserted-by":"crossref","first-page":"1123","DOI":"10.1038\/sj.bjc.6605605","article-title":"Chemoradiation for the treatment of epidermoid anal cancer: 13-year follow-up of the first randomised UKCCCR Anal Cancer Trial (ACT I)","volume":"102","author":"Northover","year":"2010","journal-title":"Br J Cancer"},{"key":"R10-20230903","doi-asserted-by":"crossref","first-page":"1141","DOI":"10.1016\/0360-3016(89)90519-1","article-title":"Epidermoid carcinoma of the anal canal treatment results and prognostic variables in a series of 242 cases","volume":"17","author":"Schlienger","year":"1989","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"R11-20230903","doi-asserted-by":"crossref","first-page":"1569","DOI":"10.1002\/1097-0142(19940315)73:6<1569::AID-CNCR2820730607>3.0.CO;2-F","article-title":"Epidermoid carcinoma of the anal canal. Results of curative-intent radiation therapy in a series of 270 patients","volume":"73","author":"Touboul","year":"1994","journal-title":"Cancer"},{"key":"R12-20230903","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1016\/S0360-3016(96)00493-2","article-title":"Conservative treatment by irradiation of epidermoid cancers of the anal canal: prognostic factors of tumoral control and complications","volume":"37","author":"Peiffert","year":"1997","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"R13-20230903","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1097\/COC.0b013e3181e9c0c0","article-title":"Squamous cell carcinoma of the anal margin: the University of Florida experience","volume":"34","author":"Balamucki","year":"2011","journal-title":"Am J Clin Oncol"},{"key":"R14-20230903","doi-asserted-by":"crossref","first-page":"1686","DOI":"10.1002\/(SICI)1097-0142(19990415)85:8<1686::AID-CNCR7>3.0.CO;2-7","article-title":"Malignant tumors of the anal canal: the spectrum of disease, treatment, and outcomes","volume":"85","author":"Klas","year":"1999","journal-title":"Cancer"},{"key":"R15-20230903","doi-asserted-by":"crossref","first-page":"106","DOI":"10.6004\/jnccn.2010.0007","article-title":"NCCN clinical practice guidelines in oncology. Anal carcinoma","volume":"8","author":"Engstrom","year":"2010","journal-title":"J Natl Compr Canc Netw"},{"key":"R16-20230903","doi-asserted-by":"crossref","first-page":"IV-3","DOI":"10.1097\/00005650-200208001-00002","article-title":"Overview of the SEER-Medicare data: content, research applications, and generalizability to the United States elderly population","volume":"40","author":"Warren","year":"2002","journal-title":"Med Care"},{"key":"R17-20230903","doi-asserted-by":"crossref","first-page":"IV-104","DOI":"10.1097\/00005650-200208001-00014","article-title":"Estimating health care costs related to cancer treatment from SEER-Medicare data","volume":"40","author":"Brown","year":"2002","journal-title":"Med Care"},{"key":"R19-20230903","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1093\/biomet\/70.1.41","article-title":"The central role of the propensity score in observational studies for causal effects","volume":"70","author":"Rosenbaum","year":"1983","journal-title":"Biometrika"},{"key":"R20-20230903","doi-asserted-by":"crossref","first-page":"295","DOI":"10.2307\/2528036","article-title":"The effectiveness of adjustment by subclassification in removing bias in observational studies","volume":"24","author":"Cochran","year":"1968","journal-title":"Biometrics"},{"key":"R21-20230903","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1080\/00273171.2011.568786","article-title":"An introduction to propensity score methods for reducing the effects of confounding in observational studies","volume":"46","author":"Austin","year":"2011","journal-title":"Multivariate Behav Res"},{"key":"R22-20230903","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1097\/JOM.0000000000000130","article-title":"Advantages of the net benefit regression framework for economic evaluations of interventions in the workplace: a case study of the cost-effectiveness of a collaborative mental health care program for people receiving short-term disability benefits for psychiatric disorders","volume":"56","author":"Hoch","year":"2014","journal-title":"J Occup Environ Med"},{"key":"R23-20230903","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1016\/j.jpainsymman.2009.04.010","article-title":"Improving efficiency and value in palliative care with net benefit regression: an introduction to a simple method for cost-effectiveness analysis with person-level data","volume":"38","author":"Hoch","year":"2009","journal-title":"J Pain Symptom Manage"},{"key":"R24-20230903","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1016\/j.radonc.2011.09.015","article-title":"Node-negative T1-T2 anal cancer: radiotherapy alone or concomitant chemoradiotherapy?","volume":"102","author":"Zilli","year":"2012","journal-title":"Radiother Oncol"},{"key":"R25-20230903","doi-asserted-by":"crossref","first-page":"796","DOI":"10.1056\/NEJMp1405158","article-title":"Updating cost-effectiveness\u2014the curious resilience of the $50,000-per-QALY threshold","volume":"371","author":"Neumann","year":"2014","journal-title":"N Engl J Med"},{"key":"R26-20230903","article-title":"Total lifetime and cancer-related costs for elderly patients diagnosed with anal cancer in the United States","author":"Deshmukh","year":"2015","journal-title":"Am J Clin Oncol"}],"container-title":["American Journal of Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/00000421-201807000-00002","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,3]],"date-time":"2023-09-03T03:08:17Z","timestamp":1693710497000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/00000421-201807000-00002"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,7]]},"references-count":24,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2018]]}},"URL":"https:\/\/doi.org\/10.1097\/coc.0000000000000339","relation":{},"ISSN":["0277-3732"],"issn-type":[{"value":"0277-3732","type":"print"}],"subject":[],"published":{"date-parts":[[2018,7]]}}}